Herpes zoster is a viral disease caused by the varicella-zoster virus (VZV). It is the same virus that causes varicella (chicken pox) in children. The virus may remain dormant in the nerves of the skull or in the back and limbs after the infection has subsided. The virus can occasionally reactivate and target people over the age of 60 because a compromised immune system makes it easier for a dormant virus to reawaken.
Elderly people are particularly vulnerable to herpes zoster. The most typical side effect is viral pain. This pain can last for weeks or even months after the rash has subsided. Occasionally, the pain does not respond to regular painkillers. Further complications may include brain injury, meningitis, pneumonia, and more.
The Herpes zoster vaccine is effective in preventing the illness and, mainly, in lowering the risk of complications.
Older adults over the age of 60 are advised to receive a vaccination (if there are no restrictions or conditions that prevent vaccination) even if they have previously had the disease, as there is a risk of the disease recurring.
A new, more effective vaccine for herpes zoster called Shingrix will be available in Israel starting in July 2023. Shingrix is given in two doses and can be administered to people with suppressed immune systems, unlike the previous vaccine. The vaccine is recommended for people over the age of 50, but the national health basket only covers it for those over the age of 65 who are considered to be at elevated risk.